(a) is a polypeptide in which (i) at least one T-cell epitope peptide comprising an amino acid sequence selected from the peptide group consisting of peptide no. 14 (SEQ ID NO: 28), 15 (SEQ ID NO: 29), 16 (SEQ ID NO: 30), 17 (SEQ ID NO: 31), 22 (SEQ ID NO: 36) and 43 (SEQ ID NO: 57) of cedar pollen allergen Cry j 1 shown in Fig. 1, is linearly bound to (ii) a T-cell epitope peptide comprising an amino acid sequence selected from the peptide group consisting of peptide no. 14 (SEQ ID NO: 97), 17 (SEQ ID NO: 100), 18 (SEQ ID NO: 101), 37 (SEQ ID NO: 120), 38 (SEQ ID NO: 121), 48 (SEQ ID NO: 131) and 69 (SEQ ID NO: 152) of cedar pollen allergen Cry j 2 shown in Fig. 2,

(b) does not substantively bind to cedar pollen allergen-specific IgE antibody in serum of cedar pollinosis patients,

(c) is capable of proliferating *in vitro* human T cell clones specific to the T cell epitope peptide within the peptides of (a)

(d) is capable of proliferating *in vitro* peripheral blood lymphocytes of a cedar pollinosis patient, and

(e) has no cysteine residues.

Please cancel claims 6, 17, 31, and 35 to 47.

Please add the following claims:

49. (New) A peptide-based immunotherapeutic agent comprising the amino acid sequence of SEQ ID NO: 1.

50. (New) A peptide-based immunotherapeutic agent comprising the amino acid sequence of SEQ ID NO: 2.

51. (New) A peptide-based immunotherapeutic agent comprising the amino acid sequence of SEQ ID NO: 3.

52. (New) A peptide-based immunotherapeutic agent for cedar pollinosis comprising an effective amount of a polypeptide, wherein said polypeptide comprises:

(a) a T-cell epitope peptide comprising at least one T-cell epitope peptide consisting of an amino acid sequence selected from the group consisting of peptide no. 14 (SEQ ID NO: 28), 15 (SEQ ID NO: 29), 16 (SEQ ID NO: 30), 17 (SEQ ID NO: 31), 22 (SEQ ID NO: 36) and 43 (SEQ ID NO: 57) of cedar pollen allergen Cry j 1 shown in Fig. 1 linearly bound to a second T-cell epitope peptide comprising at least one T-cell epitope peptide consisting of an amino acid sequence selected from the group consisting of peptide no. 14 (SEQ ID NO: 97), 17 (SEQ ID NO: 100), 18 (SEQ ID NO: 101), 37 (SEQ ID NO: 120), 38 (SEQ ID NO: 121), 48 (SEQ ID NO: 131) and 69 (SEQ ID NO: 152) of cedar pollen allergen Cry j 2 shown in Fig. 2.

53. (New) The peptide-based immunotherapeutic agent according to claim 52, wherein said agent does not substantively bind to cedar pollen allergen-specific IgE antibody in serum of cedar pollinosis patients.

54. (New) The peptide-based immunotherapeutic agent according to claim 53, wherein said agent is capable of proliferating *in vitro* human T cell clones specific to the T cell epitope peptides.

55. (New) The peptide-based immunotherapeutic agent according to claim 54, wherein said agent is capable of proliferating *in vitro* peripheral blood lymphocytes of a cedar pollinosis patient.

56. (New) The peptide-based immunotherapeutic agent according to claim 55, wherein said agent has no cysteine residues.

57. (New) The peptide-based immunotherapeutic agent according to claim 52, wherein said agent further comprises a cleavage site between said T-cell epitope peptides.

58. (New) The peptide-based immunotherapeutic agent according to claim 56, wherein said agent further comprises a cleavage site between said T-cell epitope peptides.

59. (New) The peptide-based immunotherapeutic agent according to claim 52, further comprising a pharmaceutically acceptable carrier or diluent.

60. (New) The peptide-based immunotherapeutic agent according to claim 58, further comprising a pharmaceutically acceptable carrier or diluent.

61. (New) The peptide-based immunotherapeutic agent according to claim 1, further comprising a pharmaceutically acceptable carrier or diluent.

62. (New) A method of treating cedar pollinosis comprising the administration of an effective amount of the peptide based immunotherapeutic agent according to claims 1, 49, 50, 51, 52, 59, 60, or 61.

63. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 1 is administered.

64. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 52 is administered.

65. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 59 is administered.

66. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 60 is administered.

67. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 61 is administered.

68. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 49 is administered.

69. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 50 is administered.

70. (New) The method according to claim 62, wherein an effective amount of the peptide based immunotherapeutic agent according to claim 51 is administered.

S:\SH-RESP\SPO\SPO-103-RES-2-13AUG2002-OA.DOC/DNB/jaj